At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 142 enrolled
Drug / intervention
EDP-323 Dose Regimen 1 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy Adults
In Brief
A Phase 2 clinical trial evaluating EDP-323 Dose Regimen 1, EDP-323 Dose Regimen 2, and 1 other intervention for RSV Infection. Completed, enrolled 142 participants across 1 site.
Detailed Summary
A randomized, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-323 in healthy subjects infected with RSV-A Memphis 37b. This study is designed to assess the antiviral effect of EDP-323 compared to a placebo control in the respiratory syncytial virus challenge model.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRSV Infection
CountriesUnited Kingdom
CollaboratorshVIVO Services Limited
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartNov 2023
First PostedDec 2023
Primary CompletionJun 2024
Study CompletionJul 2024
TodayJul 2026
First PostedDec 14, 2023
Enrollment StartNov 20, 2023
Primary CompletionJun 17, 2024
Study CompletionJul 12, 2024
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 2.6 years ago
Interventions
EDP-323 Dose Regimen 1drug
EDP-323 capsule
EDP-323 Dose Regimen 2drug
EDP-323 capsule
Placebodrug
Placebo capsule